Method for treatment of cardiac disorders

A method comprising:

• determining a rate of delivery of a therapeutic protein formulation from an implantable source through an implantable catheter directly to a pericardial sac region of a heart of a patient,
• wherein the patient has a cardiac disorder caused by a protein deficiency due to a gene mutation,
• wherein the therapeutic protein formulation comprises a protein in a form that is deficient in cardiac cells of the patient due to the gene mutation, and
• wherein the therapeutic protein formulation is delivered at a rate based on the the sequence of the patent's gene encoding the deficient protein;
• delivering the therapeutic protein formulation from the implantable source through the implantable catheter directly to the pericardial sac region of the heart of the patient;
• and
• wherein the cardiac disorder and the protein deficiency are selected from:
• Mucopolysaccharidoese Hurler (MPS IH) and α-L-iduronidase;
• Schie (MPS IS) and α-L-iduronidase;
• Hunter (MPS II) and Sulfoiduranate sulfate;
• Marquio syndrome (Mucopolysaccharidosis II) and β-Galactosidase;
• Maroteaux-Lamy syndrome (MPS VI) and Aryl sulfatase B;
• Mucolipidoses I cell disease (Mucolipidosis II) and N-acetylglucosamine-I-phosphotransferase;
• PseudoHurler polydystrophy (Mucolipidoses III) and N-acetylglucosamine-I-phosphotransferase;
• Sphingolipidoses Gaucher disease Type I and Glucocerebrosidase;
• Type III Glycogenosis and Amlo-1,6-glucosidase;
• Acyl-CoA Dehydrogenase Deficiencies LCAD Deficiency and Long-chain acylCoA dehydrogenase;
• Primar Hyperoxaluria I and glyoxylate amino transferase;
• Primary Hyperoxaluria II and D-glyceric acid dehydrogenase;
• Homocystinuria and Cystathionine;
• Triose-phosphate isomerase deficiency and Triose-phosphate isomerase;
• Hereditary Orotic Aciduria and Uridine-5′-monophosphate synthase;
• Amyloidosis and Prealbumin;
• and
• Refsum's disease and Phytanic acid α hydroxylase.

A method comprising:

• injecting a therapeutic protein formulation into an implantable source;
• and
• delivering the therapeutic protein formulation from an implantable source through an implantable catheter directly to a pericardial sac region of a heart of a patient,
• wherein the patient has a cardiac disorder caused by a protein deficiency due to a gene mutation,
• wherein the therapeutic protein formulation comprises a protein in a form that is deficient in cardiac cells of the patient due to the gene mutation, and
• wherein the therapeutic protein formulation is delivered at a rate based on the sequence of the patient's gene encoding the deficient protein;
• wherein the cardiac disorder and the protein deficiency are selected from:
• Mucopolvsaccharidoese Hurler (MPS IH) and α-L-iduronidase;
• Schie (MPS IS) and α-L-iduronidase;
• Hunter (MPS II) and Sulfoiduranate sulfate;
• Marquio syndrome (Mucopolysaccharidosis II) and β-Galactosidase;
• Maroteaux-Lamy syndrome (MPS VI) and Aryl sulfatase B;
• Mucolipidoses I cell disease (Mucolipidosis II) and N-acetylglucosamine-I-phosphotransferase;
• PseudoHurler polydystrophy (Mucolipidoses III) and N-acetylglucosamine-I-phosphotransferase;
• Sphingolipidoses Gaucher disease Type I and Glucocerebrosidase;
• Type III Glycogenosis and Amlo-1,6-glucosidase;
• Acyl-CoA Dehydrogenase Deficiencies LCAD Deficiency and Long-chain acylCoA dehydrogenase;
• Primary Hyperoxaluria I and Alumine:
• glyoxylate amino transferase;
• Primary Hyperoxaluria II and D-glyceric acid dehydrogenase;
• Homocystinuria and Cystathionine;
• Triose-phosphate isomerase deficiency and Triose-phosphate isomerase;
• Hereditary Orotic Aciduria and Uridine-5′-monophosphate synthase;
• Amyloidosis and Prealbumin;
• and
• Refsum's disease and Phytanic acid α hydroxylase.